Piramal Pharma Ltd
Piramal Pharma Ltd (PPLPHARMA) last reported results for the quarter ended Jun 2026, with sales of ₹2,270 crore and net profit of ₹-69 crore. Piramal Pharma Ltd’s board meets on 19 Oct 2026. The stock last traded at ₹198, a market capitalisation of ₹26,294 crore. Over the past 52 weeks the stock has ranged between ₹132 and ₹232. Figures are as of 6 Oct 2026 and are not real time.
Piramal Pharma Ltd share price and key metrics
- Current price
- ₹198
- Market cap
- ₹26,294 cr
- Book value
- ₹61.4
- ROE
- -3.83%
- ROCE
- 2.52%
- Dividend yield
- 0.00%
- 52w high / low
- 232/132
Metrics as of 6 Oct 2026. Not real time.
Track Piramal Pharma Ltd
Cruxal reads every Piramal Pharma Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Piramal Pharma Ltd growth and returns
- 10 Years
- %
- 5 Years
- 7%
- 3 Years
- 8%
- TTM
- 1%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- -31%
- TTM
- -296%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 25%
- 1 Year
- 0%
- 10 Years
- %
- 5 Years
- 0%
- 3 Years
- -1%
- Last Year
- -4%
Piramal Pharma Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹2,270 cr, up 17.4% from ₹1,934 cr a year earlier. Net profit was ₹-69 cr, up 15.9% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 2,242 | 2,204 | 2,754 | 1,934 | 2,044 | 2,140 | 2,752 | 2,270 |
| Expenses | 1,900 | 1,866 | 2,193 | 1,827 | 1,885 | 1,944 | 2,291 | 2,075 |
| Operating profit | 342 | 338 | 561 | 107 | 159 | 196 | 461 | 195 |
| OPM % | 15% | 15% | 20% | 6% | 8% | 9% | 17% | 9% |
| Other income | 78 | 29 | 58 | 98 | 80 | 12 | -116 | 109 |
| Interest | 108 | 103 | 104 | 86 | 82 | 89 | 83 | 88 |
| Depreciation | 192 | 197 | 243 | 197 | 203 | 213 | 218 | 224 |
| Profit before tax | 120 | 67 | 273 | -79 | -46 | -94 | 43 | -7 |
| Tax % | 81% | 94% | 44% | 3% | 115% | 45% | 121% | 830% |
| Net profit | 23 | 4 | 154 | -82 | -99 | -136 | -9 | -69 |
| EPS (₹) | 0.17 | 0.03 | 1.16 | -0.61 | -0.75 | -1.02 | -0.07 | -0.52 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Piramal Pharma Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 6,315 | 6,559 | 7,082 | 8,171 | 9,151 | 8,869 | 9,205 |
| Operating profit | 1,428 | 950 | 629 | 1,197 | 1,445 | 922 | 1,010 |
| OPM % | 23% | 14% | 9% | 15% | 16% | 10% | 11% |
| Net profit | 835 | 376 | -186 | 18 | 91 | -326 | -314 |
| EPS (₹) | — | — | -1.41 | 0.13 | 0.69 | -2.45 | -2.36 |
TTM is the trailing twelve months to the most recent quarter.
Piramal Pharma Ltd balance sheet
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 995 | 1,186 | 1,193 | 1,323 | 1,324 | 1,327 |
| Reserves | 4,610 | 5,511 | 5,580 | 6,588 | 6,801 | 6,835 |
| Borrowings | 3,025 | 4,128 | 5,637 | 4,710 | 4,856 | 5,675 |
| Other liabilities | 2,047 | 1,781 | 1,893 | 2,461 | 2,447 | 3,770 |
| Total liabilities | 10,677 | 12,605 | 14,303 | 15,083 | 15,429 | 17,607 |
| Fixed assets | 6,105 | 6,879 | 7,469 | 7,990 | 8,133 | 8,684 |
| CWIP | 627 | 1,172 | 1,419 | 1,116 | 977 | 1,100 |
| Investments | 123 | 267 | 639 | 385 | 291 | 437 |
| Other assets | 3,822 | 4,286 | 4,777 | 5,592 | 6,028 | 7,386 |
| Total assets | 10,677 | 12,605 | 14,303 | 15,083 | 15,429 | 17,607 |
As reported by the company. Total assets equal total liabilities by construction.
Piramal Pharma Ltd cash flow
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Cash from operations | 598 | 766 | 484 | 1,005 | 892 | 1,653 |
| Cash from investing | -4,464 | -1,737 | -1,334 | -416 | -488 | -820 |
| Cash from financing | 3,977 | 794 | 818 | -422 | -441 | -39 |
| Net cash flow | 110 | -177 | -32 | 166 | -37 | 794 |
| Free cash flow | -5 | -91 | -461 | 294 | 233 | 776 |
| CFO / operating profit | 52% | 98% | 107% | 97% | 85% | 202% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Piramal Pharma Ltd operating ratios
| Per year | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| ROCE % | — | 7% | 2% | 5% | 6% | 3% |
| Debtor days | 91 | 99 | 93 | 95 | 94 | 89 |
| Inventory days | 218 | 207 | 227 | 269 | 261 | 345 |
| Days payable | 163 | 153 | 161 | 190 | 173 | 279 |
| Cash conversion cycle | 147 | 153 | 159 | 174 | 182 | 155 |
| Working capital days | 44 | 36 | 13 | 21 | 60 | 44 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Piramal Pharma Ltd shareholding pattern
Promoters held 34.80% at Jun 2026, broadly unchanged since Jun 2025. FIIs 12.51% and DIIs 14.57%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 34.94% | 34.94% | 34.94% | 34.85% | 34.85% | 34.85% | 34.85% | 34.80% |
| FIIs | 31.73% | 31.68% | 31.49% | 30.86% | 30.27% | 29.66% | 30.17% | 12.51% |
| DIIs | 13.80% | 14.09% | 14.78% | 14.25% | 14.89% | 15.68% | 15.61% | 14.57% |
| Public | 19.06% | 18.85% | 18.42% | 19.46% | 19.46% | 19.35% | 19.01% | 37.62% |
| No. of shareholders | 3,59,751 | 4,18,442 | 4,32,843 | 4,58,430 | 4,62,511 | 4,53,830 | 4,50,661 | 4,61,096 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
When does Piramal Pharma Ltd’s board next meet?
Piramal Pharma Ltd’s board meets on 19 Oct 2026.
- Board meetingManagement change - appointment of new President and COO
See the full results calendar for every Indian company reporting in the next 30 days.
Piramal Pharma Ltd corporate filings
- Piramal Pharma Ltd discloses expiry and non-renewal of commercial arrangement with Bayer PharmaceuticalsCompany Updatelow impact
Cruxal's analysis: The company announced the expiry and non-renewal of a commercial arrangement with Bayer…
Read the full analysis - Piramal Pharma clarifies news on Ontario's $1.7 million investment at Aurora facilityCompany Updatelow impact
Cruxal's analysis: Piramal Pharma issued a clarification regarding a news report dated September 30, 2026…
Read the full analysis - Piramal Pharma Limited appoints Mr. Viral Gandhi as Chief Technology Officer, effective 1st October 2026Company Updatelow impact
Cruxal's analysis: Piramal Pharma Limited announced the appointment of Mr. Viral Gandhi as Chief Technology…
Read the full analysis - Piramal Pharma Announces Senior Management Transition, Retiring COO Jeffrey Hampton and Appointing New President & COO Brian GuyCompany Updatemedium impact
Cruxal's analysis: Piramal Pharma Limited disclosed that Jeffrey Hampton, President and COO of Piramal…
Read the full analysis - Closure of Trading WindowInsider Trading / SASTlow impact
Cruxal's analysis: Please refer the attachment.
Read the full analysis - Piramal Pharma Ltd: Routine Regulatory Disclosure Under Regulation 30Company Updatelow impact
Cruxal's analysis: Piramal Pharma Ltd has filed a routine disclosure under Regulation 30 of the SEBI (LODR)…
Read the full analysis - Piramal Pharma Ltd discloses ESG rating certificationCompany Updatelow impact
Cruxal's analysis: Piramal Pharma Ltd has filed a disclosure under Regulation 30 regarding an ESG rating…
Read the full analysis - Piramal Pharma Ltd discloses FDA inspection update under Regulation 30Company Updatelow impact
Cruxal's analysis: Piramal Pharma has filed a disclosure regarding a US FDA inspection in compliance with…
Read the full analysis - Piramal Pharma Ltd schedules analyst/investor meetingCompany Updatelow impact
Cruxal's analysis: Piramal Pharma Ltd has issued an intimation regarding an upcoming analyst/investor meet…
Read the full analysis - Piramal Pharma Ltd discloses ESG rating updateCompany Updatelow impact
Cruxal's analysis: Piramal Pharma Ltd has submitted a disclosure under Regulation 30 of the SEBI (LODR)…
Read the full analysis - Piramal Pharma Limited: Re-creation of Pledge on 9.84 crore Shares by CA Alchemy InvestmentsInsider Trading / SASTlow impact
Cruxal's analysis: Piramal Pharma Limited has reported that CA Alchemy Investments has re-created a pledge…
Read the full analysis - Piramal Pharma Ltd releases Sustainability Report for FY 2025-26Company Updatelow impact
Cruxal's analysis: Piramal Pharma Limited has filed its Sustainability Report for the financial year…
Read the full analysis - Piramal Pharma Limited acquires majority 74% stake in Yapan Bio for 76 croreCompany Updatehigh impact
Cruxal's analysis: Piramal Pharma Limited has completed the acquisition of an additional 40.67% stake in…
Read the full analysis - Piramal Pharma Limited: Deutsche Bank releases pledge on 9.84 crore shares following permitted sale transactionInsider Trading / SASTmedium impact
Cruxal's analysis: Piramal Pharma Limited has seen a reduction in encumbered shares as Deutsche Bank AG…
Read the full analysis - Piramal Pharma to acquire majority stake in Yapan Bio, transitioning associate to subsidiaryCompany Updatehigh impact
Cruxal's analysis: Piramal Pharma Limited has announced the exercise of a call option to acquire an…
Read the full analysis - Piramal Pharma Ltd schedules analyst and institutional investor meetingsCompany Updatelow impact
Cruxal's analysis: Piramal Pharma Ltd has issued an intimation regarding scheduled meetings with analysts…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.